Quanta BioDesign, Ltd. hires internationally recognized biotechnology expert Greg Hermanson to develop new life science products.
For Immediate Publication
January 15, 2020, Plain City, Ohio
Greg T. Hermanson, Ph.D., an internationally recognized expert in biotechnology, bioconjugation, and product development, has joined Quanta BioDesign, Ltd., as Chief Technology Development Officer, Life Sciences. In this newly created position, Greg will leverage Quanta BioDesign’s unique portfolio of dPEG® products to develop new products for life sciences applications. Greg has over 40 years of experience in biotechnology, bioconjugation, and product development. He is the author of numerous widely cited journal articles and four books, including the justifiably renowned Bioconjugate Techniques (Academic Press), now in its third edition, which has become an industry-standard reference work in biotechnology. Greg previously retired from Pierce Biotechnology (now part of Thermo Fisher Scientific) after 37 years and opened Greg T. Hermanson, Inc., a respected biotechnology consulting service that he still operates.
“Bringing Greg on board fulfills a dream of mine to work with him synergistically. Greg’s immense creativity, combined with a passion for Quanta BioDesign’s dPEG® technology, allows all of us to develop transformative products that will dramatically improve clinical diagnostics and life sciences applications.” Paul D. Davis, Ph.D., Founder, President, & CEO of Quanta BioDesign, Ltd.
Greg wanted to get back to developing novel technologies for bioscience.
After retiring from Thermo Fisher Scientific, Greg could have run his consulting business and spoiled his grandchildren. However, science is one of Greg’s lifelong passions, especially making new biotechnology products and finding new applications for existing products. Greg felt a strong need to get back to the lab and be creative. Greg and Paul D. Davis, Quanta BioDesign’s Founder, President, and CEO, have been friends for years. Paul was looking for someone to help him expand the company’s unique products into new areas. Need met opportunity, and Greg joined Quanta BioDesign.
With Greg’s expertise in and passion for new product development, Quanta BioDesign looks forward to bringing forward a unique portfolio of products for life sciences applications. These new products initially will focus on diagnostic applications. The anticipated benefits of these new products include improved stability, enhanced sensitivity, and fewer non-specific interactions that give rise to off-target effects and false diagnostic results.
Founded in 1997 by Paul D. Davis, Ph.D., and renamed in 1999, Quanta BioDesign, Ltd. is the world’s leading developer, innovator, and manufacturer of single molecular weight, discrete chain-length polyethylene glycol derivatives, which the company sells under the dPEG® tradename. These monodispersed PEG products are transforming biotechnology, pharmaceuticals, medical diagnostics, theranostics, nanotechnology, and many other areas of science and medicine. Quanta BioDesign, Ltd. is a made-in-America success story. Located in Plain City, Ohio, a suburb of Ohio’s capital city, Columbus, Quanta BioDesign’s operations are based entirely in the United States. Sales of dPEG® products are global. Over 1,200 scientific journal articles report the successful use of Quanta BioDesign’s dPEG® products. Also, the company’s products have been mentioned or used in more than 600 patent applications worldwide.
For more information, please contact:
Robert H. Woodman